The FDA has approved Incyte's Opzelura cream for atopic dermatitis, commonly called eczema, becoming the first and only topical JAK inhibitor registered in the US. Opzelura (ruxolitinib ...

The FDA had been due ... and caregivers.” Approval in atopic dermatitis could unlock additional sales momentum for Zoryve, which is available in a 0.3% cream for psoriasis and a 0.3% topical ...

This application seeks approval for the treatment of mild to moderate atopic dermatitis or AD in children aged 2 to 5 years. The US regulatory agency's decision on the sNDA for ZORYVE cream 0.05% ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription.

Therapy for atopic ... dermatitis. These medications also have anti-inflammatory affects, but do not contain steroids. The two medications offered are pimecrolimus and tacrolimus, and both are ...

Atopic dermatitis highlights from AAD 2025 include phase 3 trial results on rocatinlimab and delgocitinib, findings on tapinarof 1% cream, and early dosing data on a new JAK1/TYK2 inhibitor.

At the ER, the doctors said it looked like atopic dermatitis ... doctors relied on over-the-counter medications and creams. Now, there are FDA-approved medications. Cramond says her eczema ...

Health Canada approves Arcutis' Zoryve cream for treating mild to moderate atopic dermatitis. Phase 3 clinical trial data shows 90% of patients experienced symptom improvement within four weeks of ...

Dupilumab's FDA approved to treat both. You might be able to kill two birds with one stone. Patient has really bad vernal conjunctivitis. So 8% of patients with atopic dermatitis have preexisting ...